News & Events - Disc Medicine

Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. (November 11, 2021) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced that the company and its collaborators at Boston Children’s Hospital have been selected to give an oral presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in Atlanta, GA on December 11-14, 2021.

Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases

CAMBRIDGE, Mass. (September 2, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced a $90 million Series B financing from a leading syndicate of investors. The financing was led by OrbiMed with participation from new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, and Alexandria Venture Investments. Existing investors also participated in the financing, including Atlas Venture, Novo Holdings and Access Biotechnology.

Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline

CAMBRIDGE, Mass. (August 23, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced the promotions of Will Savage, MD, PhD to Chief Medical Officer and Jonathan Yu to Chief Business Officer. In addition, the company has expanded its scientific leadership with the appointments of industry veterans Hua Yang, PhD, as Vice President of Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as Vice President of Regulatory Affairs.

Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation

CAMBRIDGE, Mass. (July 28, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced the initiation of the first-in-human, Phase 1 study in healthy subjects of DISC-0974, a first-in-class inhibitor of hemojuvelin (HJV), a novel, genetically validated target for modulating iron metabolism and red blood cell formation. DISC-0974 is being developed as a potential treatment for anemia of inflammation.

Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis

CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche Ltd for the development and commercialization of bitopertin, an orally administered GlyT1 inhibitor with demonstrated effects on the heme biosynthesis pathway. Disc Medicine intends to develop bitopertin as a treatment for hematologic diseases, initially for erythropoietic porphyrias (EP), a family of rare, debilitating and potentially life-threatening disorders caused by dysregulated heme biosynthesis in developing red blood cells.

Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress

CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association (EHA) 2021 Virtual Congress, which will be held from June 9-17.

Disc Medicine to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will provide a corporate presentation on Thursday, June 3, 2021 at 2:00 p.m. ET at the Jefferies Virtual Healthcare Conference.

Disc Medicine Appoints William White to its Board of Directors

CAMBRIDGE, Mass. (January 13th, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that it has appointed William White to its Board of Directors. “We are delighted to welcome Bill to Disc Medicine’s Board of Directors,” said Chief Executive Officer John Quisel, JD, PhD.

Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting &…

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass. (November 23, 2020) – Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation by John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will be…

Disc Medicine Expands Scientific Advisory Board with Leading Experts in Hepcidin Biology

Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced the appointment of Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD…

Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference

Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi’s 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020…

Disc Medicine Expands Leadership Team with Industry Veterans to Advance Hepcidin Modulating Therapies Toward the Clinic

Jonathan Yu Named Senior Vice President of Corporate Strategy William Savage, MD, PhD Appointed Vice President of Clinical Development

John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer

Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced the appointment of John Quisel, JD, PhD as President and Chief Executive Officer effective February 25, 2020. Dr. Quisel joins Disc Medicine after more than a decade at Acceleron Pharma where he most recently was Chief Business Officer. In this planned transition, co-founder and interim CEO, Brian MacDonald, will continue to serve as a senior advisor and director of the company.

Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production

Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced the completion of a $50 million Series A financing. The company’s novel approach focuses on targeting hepcidin, a key regulator of iron metabolism, as a treatment for inherited and acquired disorders of erythropoiesis.

Disc Medicine Expands Pipeline Focused on Hepcidin Pathway

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicine, a hematology company that is applying new insights in hepcidin biology to develop therapies addressing ineffective red blood cell production in hematologic diseases, today announced that it has entered into an exclusive license…

Introducing Disc Medicine, a New Hematology Company

Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions (erythropoiesis). Focused on the hepcidin pathway, the master regulator of iron metabolism and the most promising consensus pathway to address a range of diseases, Disc is advancing first-in-class therapies to transform how hematologic disease is treated.